About the Company
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XLRN News
Acceleron Pharma
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication ...
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
Merck added sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021. The drug will carry a list price of $14,000 per vial, as most patients will use single vial every three ...
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021, underscoring the company’s commitment to advancing innovative therapies for serious medical conditions.
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Mr. Dable is on three public biopharmaceutical company boards and was previously Chief Executive Officer of Acceleron Pharma Inc. at the time of its sale to Merck & Co., Inc. Mr. Santel serves on the ...
Merck & Co., Inc. (MRCK34.SA)
which it acquired by buying Acceleron Pharma, to help soften the blow when Keytruda loses patent protection later this decade. Merck’s $11.5 Billion Bet on Its Next Big Drug Finally Arrives ...
Nosebleed News and Research
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature ...
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
Merck added sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021. Winrevair is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class ...
Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within ...
Loading the latest forecasts...